# Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

> **NCT02379416** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 47 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Nilotinib + Paclitaxel

## Key facts

- **NCT ID:** NCT02379416
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-13
- **Primary completion:** 2025-04-30
- **Final completion:** 2026-02-25
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02379416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02379416, "Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02379416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*